Background. Between 2004 and 2010, the chikungunya virus (CHIKV) spread from East Africa, India, Southeast Asia to China, affected millions of people. There exists no previous report on chikungunya in HIV patients. Therefore, we studied the clinical pictures of chikungunya in HIV patients and examined whether HIV infection worsened the clinical course of chikungunya.
Methods. This is a retrospective case review of all laboratory-confirmed cases of chikungunya fever (CHIKF) from August 2008-September 2009 at Songklanagarind Hospital, a teaching hospital in Southern Thailand. We compared the demographic data, clinical course, severity, and complication of CHIKF in HIV and non-HIV patients. CD4 cell count and HIV viral load were also assessed in CHIKV-coinfected HIV patients.
Results. Thirteen HIV patients (CD4 cell count range of 250-873 cells/μL) and 71 non-HIV patients with CHIKF were identified. There were no significant differences in the demographic data and clinical course, except HIV patients were younger (mean age ± SD, 36± 4 years vs 42 ± 14 years, P= 0.005). All patients presented with fever and bilateral arthralgia. Eighty-four percent of both groups developed rash. The median duration of arthralgia and rash was 14 days and 3 days, respectively. However, more non-HIV patients needed opioid analgesics (tramadol) (50% vs 9.1%, P = 0.018), and were more likely to temporarily stop working (83.6% vs 46.2%, P = 0.007). None of the HIV patients were hospitalized, developed complication or had chronic arthritis, compared with 11.2%, 5.6%, and 2.8% of non-HIV patients, respectively. There was no HIV viral load rebound in the previously viral suppressed HIV patients during or after CHIKF. Two HIV patients, in whom pre-CHIKF illness HIV viral load was 3,630 and 30,100 copies/mL, had their HIV viral load decrease to 901 and 17,500 copies/ mL after 1 and 21 days of CHIKV infection, respectively. Long term follow-up (16-32 months post chikungunya) did not detect any alarming fall in blood CD4 counts in any of the HIV patients.
Conclusion. HIV infection did not worsen the clinical course of CHIKF. CHIKV also had no adverse effects upon CD4 cell count or HIV viral load.
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